企业品牌价值排行,中国企业品牌价值排行,世界900强品牌价值排行榜单,专业品牌价值评价平台-Baidu Says It Needs Six Years before It Launches Its Metaverse App, XiRang 企业品牌价值排行|中国企业品牌价值排行|世界900强品牌价值排行榜单|专业品牌价值评价平台
中国品牌价值评价标准

Baidu Says It Needs Six Years before It Launches Its Metaverse App, XiRang

2021-12-27 17:15:33    来源:Daguan Keweiwei

2.png


        According to media, Baidu plans to hold its annual developers’ event Monday in the virtual world of its metaverse app, XiRang. The company claims it will be China’s first metaverse conference.

 

        However, the development of the app began last December, but it is still needs at least six years to full launch. , Ma Jie, a vice president at Baidu, told reporters that in response to questions such as one asking for details on that timeline, Ma struck an apologetic tone: “That’s a very good question, but I may not have a very good answer.”

 

        Baidu's app can now host 100,000 virtual attendees for the conference, Ma said, showing reporters a graphic rendering of the virtual stadium. He said said that Baidu aims to build an open-source platform for metaverse developers — an infrastructure for a virtual world.

 

 

        About Baidu

        

Baidu is a leading AI company with a strong Internet foundation. Its vision is to become the world's top high-tech company that understands users best and can help people grow. Baidu has tens of thousands of R&D engineers, which is the top technical team in China and even the world. This team masters the world’s most advanced search engine technology, making Baidu a Chinese high-tech company that masters the world’s cutting-edge science and core technology, and also making China the only four companies in the world that own the United States, Russia, and South Korea. One of the countries with the core technology of search engines.


        On the ranking of “The First Daguan · Keweiwei World Brand Value Top 900" released on March 14, 2021, Baidu's brand value was 80.058 billion RMB, ranking the 363rd.


文章最后图片.png


作者:Nan

浏览量:171441

   

   

   



相关新闻全部阅读

阅读下一篇

哮喘重磅新药,安进(Amgen)/阿斯利康(AstraZeneca)TSLP抑制剂Tezspire获FDA批准上市

近日,安进与阿斯利康联合宣布,其TSLP抑制剂Tezspire正式获FDA批准上市,用于12岁及以上重症哮喘患者的附加维持治疗,成为首个可持续显著降低广泛重症哮喘患者群体病情恶化的生物制剂。

返回首页
返回新闻页面